Evidence map›Paper›PMID 34059694›Full record

ArticleScientific reports2021

High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells.

Hande Topel, Ezgi Bağırsakçı, Yeliz Yılmaz, Ayşim Güneş, Gülsün Bağcı, Dehan Çömez, Erkan Kahraman, Peyda Korhan, Neşe Atabey

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Hyperglycemia AltersIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hande TopelIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Ezgi BağırsakçıIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Yeliz YılmazIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Ayşim GüneşIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Gülsün BağcıIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Dehan ÇömezIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Erkan KahramanIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Peyda KorhanIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey.
Neşe AtabeyIzmir Biomedicine and Genome Center (IBG), Balcova, 35340, Izmir, Turkey. nese.atabey@ibg.edu.tr.
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is strongly associated with metabolic dysregulations/deregulations and hyperglycemia is a common metabolic disturbance in metabolic diseases. Hyperglycemia is defined to promote epithelial to mesenchymal transition (EMT) of cancer cells in various cancers but its molecular contribution to HCC progression and aggressiveness is relatively unclear. In this study, we analyzed the molecular mechanisms behind the hyperglycemia-induced EMT in HCC cell lines. Here, we report that high glucose promotes EMT through activating c-Met receptor tyrosine kinase via promoting its ligand-independent homodimerization. c-Met activation is critical for high glucose induced acquisition of mesenchymal phenotype, survival under high glucose stress and reprogramming of cellular metabolism by modulating glucose metabolism gene expression to promote aggressiveness in HCC cells. The crucial role of c-Met in high glucose induced EMT and aggressiveness may be the potential link between metabolic syndrome-related hepatocarcinogenesis and/or HCC progression. Considering c-Met inhibition in hyperglycemic patients would be an important complementary strategy for therapy that favors sensitization of HCC cells to therapeutics.

Indexed as

Carcinoma, HepatocellularCell Line, TumorCell MovementDimerizationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGlucoseGlycolysisHumansLiver NeoplasmsNeoplasm InvasivenessReceptor Protein-Tyrosine KinasesSignal TransductionGlucoseReceptor Protein-Tyrosine KinasesRON protein

Identifiers

PMID34059694
PMCPMC8166976
OpenAlexW3164890581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.